VIRIDIAN THERAPEUTICS INC. - COMMON STOCK

Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

09 May 2023 15:01:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections

08 May 2023 07:00:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 May 2023 15:05:00 By Nasdaq GlobeNewswire

Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023

02 May 2023 07:00:02 By Nasdaq GlobeNewswire

UPDATE – Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology

20 Apr 2023 12:41:48 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology

20 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Apr 2023 15:05:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

08 Mar 2023 06:00:01 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society

07 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023

01 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Viridian Therapeutics to Participate in Cowen’s 43rd Annual Health Care Conference

28 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

07 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

Viridian Appoints Scott Myers as President and Chief Executive Officer

06 Feb 2023 06:00:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

02 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)

08 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jan 2023 15:05:00 By Nasdaq GlobeNewswire

Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye Disease

21 Dec 2022 06:00:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Dec 2022 15:05:00 By Nasdaq GlobeNewswire